Reports Q2 revenue $3.021M vs $0 last year. “This is an exciting time for Trevena as we near completion of proof-of-concept studies evaluating the potential for use of TRV045 in both epilepsy and pain,” said Carrie Bourdow, President and CEO of Trevena. “We anticipate achieving a range of other milestones in Q3, including new respiratory data for OLINVYK and receipt of a non-dilutive $15 million tranche from our ex-US royalty based financing. We look forward to updating you as these developments occur.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TRVN: